Compare Citius Pharmaceuticals Inc (CTXR) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Tapestry, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Tapestry, Inc. trades at $116.99 (market cap $23.09B). The key difference: Tapestry, Inc. is far larger — about 1695.3× Citius Pharmaceuticals Inc's market cap, and Tapestry, Inc. pays a 1.6% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Tapestry, Inc. for 70 Days on average.
| CTXR | TPR | |
|---|---|---|
Market Cap | $13.62M | $23.09B |
Volume | 132,438 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $164.78 |
52-Week Low | $0.48 | $98.81 |
Typical Hold Time | 16 Days | 70 Days |
Enterprise Value | $3.79M | $25.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
TPR trades at $113.39, down 2.86% today, with a bearish technical signal from moving averages. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined significantly to $183M from $816M in 2024. Recent earnings beats and a 73% analyst buy rating support optimism, while technical indicators show resistance near $114-116. The stock trades at a P/E of 15.93, below the consensus price target of $174.64.
Outlook remains positive based on analyst consensus and earnings momentum, but risks include Kate Spade execution challenges, tariff pressures, and volatile cash flows. The current price offers potential upside to targets, though technical weakness near-term requires monitoring support at $111-113. Revenue growth to $8B in 2026 with margin expansion could drive valuation if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
